Critical2/2 relationships sourcedProfile verified Sep 7, 2026
OverviewIndicatorsMore SignalsSourcesM&A fitRelationship mapStoryMilestonesHistory

30-Second Executive Brief

Executive Assessment

Eli Lilly functions as a systemically important institution within Healthcare & Life Sciences, backed by 80% sourcing coverage, with accelerating strategic relevance.

  • Maintains 2 mapped relationships across the graph
  • 80% sourcing coverage across sourced relationships
  • Tracked as systemically important institution within the Healthcare & Life Sciences category

Executive Snapshot

Strategic Role
Systemically Important Institution
Sourcing Coverage
80%
View Methodology →

Computed live from this entity's own relationships and evidence: how many relationships carry at least one linked citation, weighted with citation recency and source type — independent of Strategic Importance, and not a prediction. Not a hand-typed number; recalculated on every read.

Ecosystem Influence
Very High
Strategic Momentum
Accelerating

Coverage

Mapped Relationships
2
Technology Domains
6

Strategic Implications

  • Central node connecting multiple strategic ecosystems
  • Directly influences technology and capital flows
  • Material relevance to downstream dependency mapping

Top Opportunities

Continued GLP-1 volume growth expected through 2026 as oral tirzepatide (Foundayo) expands access beyond injectable formulations.The pending $2.88 billion Merida Biosciences acquisition (expected to close Q4 2026) signals continued diversification of Lilly's pipeline into immunology, reducing long-term reliance on the GLP-1 franchise alone.

Top Risks

Pricing pressure and intensifying competition from Novo Nordisk's oral semaglutide could erode Lilly's GLP-1 market share advantage.Heavy revenue concentration in the GLP-1 franchise increases sensitivity to any manufacturing, safety, or reimbursement setback in that drug class.

Critical Dependencies

Continue to Dependency Graph ↓

The world's largest pharmaceutical company by market capitalization, driven by dominant GLP-1 franchises Mounjaro (diabetes) and Zepbound (obesity). Lilly raised its full-year 2026 revenue guidance to $85-87 billion after a Q2 2026 beat, with Mounjaro generating $8.7 billion and Zepbound $4.2 billion in the quarter; the FDA approval of oral tirzepatide pill Foundayo earlier in 2026 extended Lilly's lead over Novo Nordisk's competing oral semaglutide. Lilly is also diversifying beyond obesity/diabetes, agreeing in August 2026 to acquire autoimmune-disease biotech Merida Biosciences for up to $2.88 billion.

⚡

Leading Indicators

Hiring and patent filing trends — the underlying numbers Momentum is computed from. Insider filing activity is tracked separately under Sources below.

Risingdriven mostly by insider filing activity, up 2 since last check
⚡

Additional Intelligence Signals

Patent citation lineage, earnings-call mentions, and federal contract disclosures — automatically collected, not yet visible anywhere else on the site.

Federal contract disclosures

Department of Veterans Affairs — $229,741: AMYVID RADIOPHARMACEUTICAL 10 MCI FLORBETAPIR F-18 INJ,SOLN

USAspending.gov · Oct 6, 2025

Department of Veterans Affairs — $52,119: F-18 AMYVID B+4

USAspending.gov · Jun 1, 2026

Department of Veterans Affairs — $2,258: AMYVID_BETA AMYLOID IMAGING

USAspending.gov · Aug 17, 2026

⚡

Sources

Every claim traced to a primary source — evidence, recent activity, and insider filing behavior, all in one place.

Evidence

3 sources

  • CNBC — Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a declinenews
  • CNBC — Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug pushnews
  • BNN Bloomberg — Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growthnews

Latest Activity

Insider Filing Activity

19Form 4 filings, trailing 90 days+2 since last week's snapshot

Counts filing frequency only — transaction direction/size wasn't parseable from the sampled filings · sourced from SEC EDGAR · as of Sep 7, 2026

Correlated Activity

Both Eli Lilly and Amgen — which depends on it — are showing accelerating Activity at the same time (1 recorded change for Amgen in the last 90 days).

Timing correlation only — not evidence of a causal link

Both Eli Lilly and Boehringer Ingelheim — which depends on it — are showing accelerating Activity at the same time (2 recorded changes for Boehringer Ingelheim in the last 90 days).

Timing correlation only — not evidence of a causal link

⚡

Acquisition & Investment Fit

AI-reasoned, generated only from entities already in InsightNodes's own graph — a hypothetical strategic-fit exercise, not real M&A intelligence or a signal that any deal is planned or in progress.

⚡

Relationship Map

The relationships surrounding Eli Lilly — ownership, dependencies, regulation, technology and market context. Click any node to make it the new center, 2 levels deep.

2 levels3 levels 🔒5 levels 🔒

Connection type

Sign in free to click a node and explore →

Click any node to make it the new center. Scroll to zoom, drag to pan.

⚡

The Story So Far (last 6 months)

Aug 2026: Q2 2026 results and raised guidance→Aug 2026: Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth→Aug 2026: Lilly's oral tirzepatide approval beat Novo's oral pill to broader distribution (unconfirmed)→Aug 2026: Agrees to acquire Merida Biosciences for up to $2.88 billion→Aug 2026: Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push

Auto-generated from this entity's dated milestones, relationship updates, and sourced evidence — not AI-written, just sorted.

Market Intelligence

Unverified

Credibly-reported claims — analyst notes, sourcing citing “people familiar with the matter,” deals where the companies involved declined to comment — that haven't been officially confirmed. Kept structurally separate from the sourced evidence above; treat as a lead worth researching further, not an established fact.

Lilly's oral tirzepatide approval beat Novo's oral pill to broader distribution

34% confidence

Lilly's Foundayo (oral tirzepatide) received FDA approval in February 2026, ahead of the broader rollout of Novo Nordisk's competing oral semaglutide formulations.

This is InsightNodes' own interpretive read: oral GLP-1 pills remove the injection-adherence barrier that has limited the addressable obesity/diabetes market, so first-mover timing on an approved, at-scale oral option matters more than incremental efficacy differences -- Lilly's earlier approval is a meaningful commercial edge worth monitoring against Novo's own oral Wegovy prescription growth (already at 3 million as of mid-2026).

InsightNodes analysis of Eli Lilly Q2 2026 results · Aug 14, 2026

Novo Nordisk
⚡

Eli Lilly's Timeline

A sourced, dated history of Eli Lilly's key moments — founding to present.

  1. Feb 2026 · FDA approves oral tirzepatide (Foundayo)

    Lilly received FDA approval for a pill version of its GLP-1 weight-loss drug, adding an oral option alongside injectable Zepbound and intensifying competition with Novo Nordisk's oral semaglutide.

  2. Aug 2026 · Q2 2026 results and raised guidance

    Lilly reported Q2 2026 revenue of $22.97 billion, beating analyst estimates, with Mounjaro at $8.7 billion and Zepbound at $4.2 billion for the quarter, and raised full-year revenue guidance to $85-87 billion.

  3. Aug 2026 · Agrees to acquire Merida Biosciences for up to $2.88 billion

    Lilly agreed to acquire privately held Merida Biosciences (Cambridge, MA) for up to $2.88 billion in cash plus contingent milestones, expanding its pipeline into immunity-related and allergic diseases; Merida's lead candidate MER511 is a Phase 1 biologic designed to target and degrade disease-causing antibodies (initially for Graves' disease and thyroid eye disease) without broadly suppressing the immune system. The deal is expected to close in Q4 2026 and continues Lilly's active 2026 dealmaking pace funded by GLP-1 profits.

⚡

How These Connections Evolved

How a relationship changed over time, not just its current state — sourced, dated, and traceable.

Eli Lilly ↔ Healthcare & Life Sciences

  1. 2015–2022 · Pre-GLP-1-boom sector position

    Eli Lilly's position within the broader healthcare & life sciences sector predates its GLP-1-driven valuation surge that began accelerating around 2022-2023 with Zepbound/Mounjaro's commercial success.

  2. Now

    Eli Lilly operates in the pharmaceutical segment of the healthcare and life sciences industry, with its GLP-1 franchise as the dominant growth driver.